ACU Q2 Earnings Surge on MyMedic Integration and Margin Expansion

• Acme United reported Q2 2026 EPS of $1.22, significantly beating estimates, driven by a 16% YoY sales increase fueled by the MyMedic acquisition and 8% organic growth.
• The company successfully expanded gross margins to 42.6% from 41.0% in the prior year, signaling effective cost management despite tariff pressures.
• Management attributes future margin recovery to easing tariff pressures and inventory normalization, while noting risks from elevated SG&A and geographic disparities.

Acme United Corporation delivered robust second-quarter 2026 financial results, significantly outperforming market consensus across key metrics. Earnings per share reached $1.22, marking a substantial beat against the consensus estimate of $0.81. Revenue also surpassed forecasts, reaching $62.7 million compared to the projected $58.1 million. This performance represents a 16% year-over-year increase in sales, highlighting strong underlying demand and successful strategic integration. The market reacted positively to these results, with shares surging nearly 18% to near their 52-week high .

The primary driver of this financial outperformance was the integration of the MyMedic acquisition. This strategic move contributed significantly to the top-line growth, adding organic growth of approximately 8% on an ex-acquisition basis . The acquisition has allowed the company to diversify its revenue streams and expand its product portfolio beyond traditional segments . Management has emphasized that the integration process is progressing well, with early indicators pointing to sustained contribution from the new business unit .

How Did Gross Margins Improve Despite Tariff Pressures?

Gross margins expanded to 42.6%, an improvement from 41.0% in the prior year period, indicating enhanced pricing power and operational efficiencies . This margin expansion occurred despite ongoing tariff-related headwinds, suggesting effective cost management strategies . Management attributes this improvement to a favorable product mix and successful cost control measures .

Looking ahead, CEO Johnsen highlighted a trajectory for continued margin recovery. The primary drivers for this outlook include the easing of tariff-related pressures and the strategic replacement of higher-tariff inventory with lower-cost stock . This inventory normalization is expected to occur gradually as the year progresses . The company anticipates that these measures will continue to support profitability in the coming quarters .

What Are the Key Risks and Future Growth Drivers?

Despite the positive performance, several risks remain that could impact future results. Selling, General, and Administrative (SG&A) expenses remain elevated at approximately 32% of sales, which could pressure net income . Additional headwinds include potential tariff and freight cost fluctuations, as well as currency volatility .

Geographic performance has been uneven, with Canada currently lagging behind other regions . Management is addressing this by focusing on expanding MyMedic beyond direct-to-consumer sales into mass retail markets . Expectations for strong fourth-quarter profitability are tied to seasonal demand patterns, which typically boost sales in the holiday period .

Investors should also monitor the integration progress of MyMedic and its ability to capture market share in new distribution channels . The company's strategic focus on expanding into mass retail could unlock significant growth potential if executed successfully . However, the elevated SG&A expenses remain a concern, and any increase could further erode margins .

The stock's positive reaction to the earnings beat reflects investor confidence in the company's ability to navigate current challenges . However, the continued elevation of SG&A expenses and geographic disparities suggest that the path to sustained profitability may require careful management . The company's ability to execute on its inventory replacement strategy and expand MyMedic's distribution will be critical in determining future performance .

Acme United's strong Q2 2026 results demonstrate the company's resilience and ability to capitalize on strategic acquisitions . The expansion of gross margins and strong organic growth provide a solid foundation for future performance . However, the risks associated with tariffs, SG&A expenses, and geographic disparities require close monitoring . Investors will be watching closely to see if the company can maintain its momentum and deliver on its forward-looking commentary .

The integration of MyMedic appears to be a key catalyst for the company's growth strategy . Management's focus on expanding into mass retail markets could significantly impact the company's long-term trajectory . However, the current elevated SG&A expenses and potential tariff fluctuations remain significant risks that could impact near-term profitability . The company's ability to navigate these challenges will be crucial in determining its future success .